

Date and Time:	12th January 2012, 10.00 – 16.00 hrs
-----------------------	---

Minutes:	
4th Guideline Development Group Meeting	
Place:	National Clinical Guidelines Centre, 180 Great Portland Street, Boardroom
Present:	<p>Nik Hirani (Chair) Angela Key Sue Copley (am) Ann Millar Malcolm Weallans Melissa Hippard Nicholas Harrison Nick Scream Patrick Wilson Tessa Lewis</p> <p>Joanna Ashe, Information Scientist (pm) Vicki Pollitt, Health Economist Izaba Younis, Research Fellow Zahra Naqvi, Research Fellow Nina Balachander, Senior Research Fellow and Project Manager Vanessa Delgado Nunes, Guideline Lead</p>
In attendance:	
Clifford Middleton, NICE Guidelines Commissioning Manager Andrew Nicholson, Consultant Histopathologist, and Professor of Respiratory Pathology	
Apologies:	
Geraldine Burge Annette Duck Richard Hubbard	

Notes

1. Nik Hirani welcomed the group to the fourth GDG meeting. Apologies were received from Geraldine Burge, Annette Duck and Richard Hubbard. The Chair asked all GDG members to declare any relevant conflicts of interest.

Andrew Nicholson declared he is an advisory for recruitment into drug trials.

Malcolm Weallans declared that since the last GDG meeting he has become a honorary treasurer for the IPF Trust.

No actions were taken following these declarations and none of the GDG members withdrew as none of the declarations conflicted with clinical areas to be discussed during the GDG meeting.

Presentations

Each of the following presentations were given:

Notes

- Pathology of a patient with IPF - Andrew Nicholson
 - Diagnostic Tools and Economic Concepts - Vicki Pollit
 - Clinical evidence review on the added value of biopsy to diagnose a patient with IPF - Nina Balachander and Zahra Naqvi
 - Further clarification on clinical questions and HE considerations - Nina Balachander and Vicki Pollit
2. AN presented an overview of the pathology of a patient with IPF, focussing on how a biopsy links into the diagnostic care pathway for an IPF patient.
 3. VP presented an introduction to diagnostic concepts and economic considerations for diagnosing a patient with IPF, using hypothetical examples.
 4. NB and ZN presented the clinical evidence review on the added value of bronchoalveolar lavage, transbronchial biopsy and surgical biopsy to diagnose a patient with IPF. The GDG acknowledged the economic considerations presented by VP and drafted recommendations for bronchoalveolar lavage, transbronchial biopsy and surgical biopsy.
 5. NB and VP presented the evidence on the added value of an MDT and Prognosis questions, seeking clarity on clinical and cost effectiveness considerations.

Any other business:

- Appraisal committee for Pirfenidone TA rescheduled for May 2012, due for publication in October 2012
- Better access to drugs for patients with rare conditions is not a guidance service but a collating of evidence which may be useful for Collaborating Centres in the future, but at present this service has not yet been established.

The meeting closed at 16.00 hrs.

Date, time and venue of the next meeting

24th February 2012, 10:00 – 16:00hrs, NCGC Boardroom